TDMS Study 05212-05 Pathology Tables
NTP Experiment-Test: 05212-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/13/96
Route: DOSED FEED Time: 09:41:08
STANDARD TREATMENT GROUPS
Facility: Battelle Columbus Laboratory
Chemical CAS #: 604-75-1
Lock Date: 05/12/94
Cage Range: All
Reasons For Removal: 25022 Accidently Killed 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include 001 0 PPM
Include 002 0 PPM
Include 003 625 PPM
Include 004 625 PPM
Include 007 2500 PPM
Include 008 2500 PPM
Include 009 5000 PPM
Include 010 5000 PPM
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05212-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/13/96
Route: DOSED FEED Time: 09:41:08
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 625 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 6 6 12 3
Moribund Sacrifice 11 18 18 16
Accidently Killed 1
Survivors
Terminal Sacrifice 32 26 20 31
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (48) (49) (50)
Polyp Adenomatous 1 (2%)
Liver (50) (50) (50) (50)
Mesentery (10) (9) (4) (6)
Pancreas (50) (50) (49) (49)
Acinus, Adenoma 1 (2%)
Stomach, Forestomach (50) (50) (50) (50)
Tongue (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adenoma 1 (2%) 1 (2%)
Adrenal Medulla (50) (50) (50) (50)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Complex 1 (2%)
Pheochromocytoma Benign 1 (2%) 3 (6%) 1 (2%)
Islets, Pancreatic (50) (50) (49) (49)
Adenoma 1 (2%)
Parathyroid Gland (42) (38) (38) (33)
Adenoma 1 (3%)
Pituitary Gland (50) (50) (50) (50)
Pars Distalis, Adenoma 30 (60%) 28 (56%) 20 (40%) 12 (24%)
Pars Distalis, Adenoma, Multiple 1 (2%) 1 (2%)
Pars Distalis, Carcinoma 1 (2%)
Page 2
NTP Experiment-Test: 05212-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/13/96
Route: DOSED FEED Time: 09:41:08
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 625 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Thyroid Gland (50) (50) (48) (49)
C-Cell, Adenoma 6 (12%) 3 (6%) 6 (13%) 2 (4%)
C-Cell, Carcinoma 1 (2%) 1 (2%) 1 (2%)
Follicular Cell, Adenoma 1 (2%) 2 (4%)
Follicular Cell, Carcinoma 1 (2%) 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (49) (50) (50) (50)
Adenoma 6 (12%) 3 (6%) 3 (6%) 4 (8%)
Carcinoma 1 (2%) 1 (2%)
Bilateral, Adenoma 1 (2%)
Ovary (50) (50) (50) (50)
Granulosa Cell Tumor Benign 1 (2%)
Tubulostromal Adenoma 1 (2%)
Uterus (50) (50) (50) (50)
Polyp Stromal 2 (4%) 4 (8%) 3 (6%) 4 (8%)
Sarcoma Stromal 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (4) (2) (9) (3)
Deep Cervical, Carcinoma, Metastatic,
Thyroid Gland 1 (25%)
Renal, Pheochromocytoma Malignant,
Metastatic, Adrenal Medulla 1 (25%)
Lymph Node, Mandibular (50) (48) (48) (49)
Lymph Node, Mesenteric (50) (50) (50) (49)
Spleen (50) (50) (50) (49)
Thymus (50) (48) (46) (47)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (49) (49) (50)
Adenoma 1 (2%) 2 (4%)
Carcinoma 2 (4%) 3 (6%)
Fibroadenoma 11 (22%) 14 (29%) 8 (16%) 12 (24%)
Fibroadenoma, Multiple 14 (29%) 5 (10%) 1 (2%) 1 (2%)
Skin (50) (50) (50) (50)
Page 3
NTP Experiment-Test: 05212-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/13/96
Route: DOSED FEED Time: 09:41:08
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 625 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Basal Cell Carcinoma 1 (2%)
Fibroma 1 (2%)
Fibrosarcoma 2 (4%)
Keratoacanthoma 1 (2%)
Trichoepithelioma 1 (2%)
Sebaceous Gland, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Astrocytoma Benign 1 (2%)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Oligodendroglioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (49) (49)
Alveolar/Bronchiolar Adenoma 2 (4%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (2)
Carcinoma 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Nephroblastoma 1 (2%)
Urinary Bladder (48) (49) (49) (50)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Page 4
NTP Experiment-Test: 05212-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/13/96
Route: DOSED FEED Time: 09:41:08
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 625 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Leukemia Mononuclear 14 (28%) 19 (38%) 29 (58%) 18 (36%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05212-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/13/96
Route: DOSED FEED Time: 09:41:08
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 PPM 625 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 49 49 45 38
Total Primary Neoplasms 101 93 80 67
Total Animals with Benign Neoplasms 43 39 30 26
Total Benign Neoplasms 77 65 45 44
Total Animals with Malignant Neoplasms 21 26 34 22
Total Malignant Neoplasms 24 28 35 23
Total Animals with Metastatic Neoplasms 2 2 1
Total Metastatic Neoplasm 2 2 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05212-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/13/96
Route: DOSED FEED Time: 09:41:08
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 625 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 25 27 33 43
Natural Death 8 12 11 7
Survivors
Terminal Sacrifice 17 11 6
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (47) (50) (50)
Polyp Adenomatous 1 (2%)
Intestine Large, Rectum (50) (48) (49) (50)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (49) (48) (46) (49)
Carcinoma 2 (4%)
Leiomyosarcoma 1 (2%)
Liver (50) (50) (49) (50)
Fibrous Histiocytoma, Metastatic, Lung 1 (2%)
Hepatocellular Carcinoma 1 (2%)
Hepatocellular Adenoma 1 (2%) 3 (6%)
Mesentery (7) (6) (4) (4)
Leiomyosarcoma, Metastatic, Intestine Small,
Jejunum 1 (14%)
Leiomyosarcoma, Metastatic, Stomach,
Glandular 1 (17%)
Oral Mucosa (1)
Gingival, Squamous Cell Carcinoma 1 (100%)
Pancreas (50) (48) (49) (50)
Adenoma 1 (2%)
Fibrous Histiocytoma, Metastatic, Lung 1 (2%)
Acinus, Adenoma 1 (2%) 1 (2%)
Acinus, Adenoma, Mixed Cell 1 (2%)
Stomach, Forestomach (50) (48) (50) (50)
Leiomyosarcoma 1 (2%)
Stomach, Glandular (50) (48) (50) (50)
Leiomyosarcoma 1 (2%)
Tongue (1) (1)
Squamous Cell Carcinoma 1 (100%)
Squamous Cell Papilloma 1 (100%)
Tooth (1)
Odontoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05212-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/13/96
Route: DOSED FEED Time: 09:41:08
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 625 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adenoma 1 (2%)
Fibrous Histiocytoma, Metastatic, Lung 1 (2%)
Adrenal Medulla (50) (50) (50) (50)
Pheochromocytoma Benign 9 (18%) 8 (16%) 5 (10%) 1 (2%)
Bilateral, Pheochromocytoma Benign 5 (10%) 1 (2%) 1 (2%) 2 (4%)
Islets, Pancreatic (50) (48) (49) (50)
Adenoma 1 (2%)
Carcinoma 2 (4%)
Pituitary Gland (49) (50) (50) (48)
Pars Distalis, Adenoma 17 (35%) 12 (24%) 9 (18%) 2 (4%)
Pars Distalis, Adenoma, Multiple 1 (2%)
Thyroid Gland (50) (49) (50) (50)
Bilateral, C-Cell, Adenoma 1 (2%) 2 (4%)
C-Cell, Adenoma 9 (18%) 5 (10%) 4 (8%) 2 (4%)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 2 (4%)
Follicular Cell, Carcinoma 3 (6%) 3 (6%) 3 (6%) 4 (8%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (2) (1) (1) (2)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (49) (50) (50)
Preputial Gland (48) (50) (50) (49)
Adenoma 6 (13%) 9 (18%) 5 (10%) 3 (6%)
Carcinoma 1 (2%)
Fibrous Histiocytoma, Metastatic, Lung 1 (2%)
Bilateral, Adenoma 1 (2%) 1 (2%)
Seminal Vesicle (50) (50) (50) (50)
Testes (50) (50) (50) (50)
Bilateral, Interstitial Cell, Adenoma 35 (70%) 42 (84%) 47 (94%) 46 (92%)
Interstitial Cell, Adenoma 10 (20%) 6 (12%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05212-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/13/96
Route: DOSED FEED Time: 09:41:08
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 625 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Lung 1 (2%)
Lymph Node (5) (8) (8) (1)
Lymph Node, Mandibular (50) (49) (49) (50)
Lymph Node, Mesenteric (49) (49) (50) (47)
Spleen (50) (50) (50) (50)
Fibroma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymus (49) (47) (49) (47)
Thymoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (44) (48) (48)
Carcinoma 1 (2%)
Fibroadenoma 4 (8%) 5 (11%) 4 (8%) 2 (4%)
Skin (50) (49) (49) (50)
Fibroma 3 (6%) 1 (2%) 1 (2%) 2 (4%)
Fibrosarcoma 2 (4%) 3 (6%)
Keratoacanthoma 3 (6%) 5 (10%) 1 (2%) 2 (4%)
Keratoacanthoma, Multiple 1 (2%)
Liposarcoma 1 (2%)
Osteosarcoma 1 (2%)
Sarcoma 1 (2%)
Schwannoma Malignant 3 (6%)
Squamous Cell Papilloma 2 (4%) 1 (2%)
Sebaceous Gland, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Chordoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Astrocytoma Malignant 1 (2%)
Fibrous Histiocytoma, Metastatic, Lung 1 (2%)
Oligodendroglioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05212-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/13/96
Route: DOSED FEED Time: 09:41:08
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 625 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%)
Chordoma, Metastatic, Bone 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Fibrous Histiocytoma 1 (2%)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (1)
Carcinoma 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Lung 1 (2%)
Renal Tubule, Adenoma 1 (2%) 3 (6%) 1 (2%)
Urinary Bladder (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Leukemia Mononuclear 27 (54%) 36 (72%) 33 (66%) 19 (38%)
Mesothelioma Malignant 2 (4%) 2 (4%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05212-05 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC OXAZEPAM Date: 09/13/96
Route: DOSED FEED Time: 09:41:08
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 PPM 625 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 50 50 50 48
Total Primary Neoplasms 160 151 135 99
Total Animals with Benign Neoplasms 47 50 50 47
Total Benign Neoplasms 115 99 89 71
Total Animals with Malignant Neoplasms 38 43 40 25
Total Malignant Neoplasms 45 52 46 28
Total Animals with Metastatic Neoplasms 3 2 1
Total Metastatic Neoplasm 3 8 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------